Feb. 25 at 12:34 PM
$ARRXF
Archer Materials reported 1H FY26 progress marked by a major technical breakthrough in its carbon-based quantum computing program, achieving on-chip electrical readout of quantum states via EDMR and SET devices and validating CMOS-compatible, wafer-scale manufacturing. The company advanced its 12CQ project with cryogenic TMR sensor performance, strengthened partnerships with Emergence Quantum and CSIRO, and remains on track for targeted qubit demonstration in 2026.
In medical diagnostics, Archer enhanced its Biochip strategy through a dual graphene and silicon platform, completing an initial silicon-based blood potassium sensor project with IMEC and demonstrating clinically aligned accuracy in human blood tests. The company is targeting a functional Biochip prototype in 2026 for point-of-care chronic kidney disease testing, supported by a strong cash position of
$10.3 million and an expanded board to accelerate R&D and commercialisation.